NASDAQ · SERVICES-PERSONAL SERVICES · SMALL CAP
Medirom Healthcare Technologies Inc. MRM
6 fiscal years on record · JPY · FY2024 reported
SEC FILINGS ONLY
Revenue · FY2024
¥8.3B
▲ 21.5% vs FY2023
EPS · FY24
¥28.52
Dividend / sh · FY24
—
Payout · FY24
—
ROE · FY24
26.0%
Net margin · FY24
1.8%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
JPY 8.3B
Revenue, FY2024 · full 6-year series below
Revenue
Net income
2 cents of every revenue dollar became profit this year.
Per share
JPY 28.52
Diluted EPS, FY2024
EPS
The company pays no cash dividend.
Profitability
26.0%
Return on equity, FY2024
ROE
Operating margin-0.2%
Net margin1.8%
Return on assets2.0%
Each JPY of equity produced 26 cents of profit this year.
Returned to shareholders
—
returned in FY2024 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+16.3% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+15.3%
+16.3%
Net income
+53.7%
EPS, diluted
+47.7%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.01B
Shares outstanding, FY2024
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
JPY 8.1B
total assets, end of FY2024
Total assetsJPY 8.1B
EquityJPY 933.3M
CashJPY 329.4M
Gross debtJPY 1.4B
Net debtJPY 1.1B
Current ratio0.65×
Net debt stands at 113% of equity.
History
6 fiscal years
Every figure from documents filed with the SEC · JPY
Metric
2024
2023
2022
2021
2020
2019
Revenue ¥B
8.3
6.8
7.0
5.4
3.3
3.9
Operating income ¥B
−0.0
−0.4
0.1
−0.5
−0.7
0.0
EBITDA ¥B
0.3
−0.1
0.3
−0.3
−0.7
0.1
Income tax ¥B
−0.1
−0.1
0.0
0.6
−0.1
0.0
Net income ¥B
0.1
0.1
0.1
−1.0
−0.5
0.0
EPS, diluted ¥
28.52
22.34
27.23
−203.13
−133.97
4.06
Dividend / sh ¥
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
ROE %
26.0
152.3
·
−700.4
−98.8
7.2
Shares out B
0.01
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
21 of 21
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed